Therapeutic management of cognitive disorders in multiple sclerosis;Prise en charge thérapeutique des troubles cognitifs dans la sclérose en plaques: Données et perspectives

Revue Neurologique

Volumn 163, Issue 6-7, 2007, Pages 703-710

  Defer, G L ^a,b,c   Daniel, F ^b,c   Derache, N ^a,c  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b Réseau Bas Normand de Prise en Charge des Patients Atteints de SEP   (France)

^c UNIVERSITÉ DE CAEN   (France)

Author keywords

Anticholinesterasic; Cognition; Cognitive training; Excitatory amino acid; Multiple sclerosis

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ANTICHOLINERGIC EFFECT; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GROUP THERAPY; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY;

EID: 34347337406     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(07)90483-x     Document Type: Conference Paper

References (60)

1. ALLEN DA, GOLDSTEIN G, ROCK A, HEYMAN MD, TIZIANA RONDINELL BS. (1998). Teaching memory strategies to persons with multiple sclerosis. J Rehabil Res Dev, 35: 405-10.
2. AREOSA SA, SHERRIFF F. (2003). Memantine for dementia. Cochrane Database Syst Rev; (3): CD003154.
3. BANWELL BL, ANDERSON PE. (2005). The cognitive burden of multiple sclerosis in children. Neurology, 64: 891-4.
4. BARAK Y, ACHIRON A. (2002). Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol, 47: 11-4.
5. BEVER CT, ANDERSON PA, LESLIE J et al. (1996). Treatment with oral 3,4-diaminopyrine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-control cressover trial. Neurology, 47: 1457-62.
6. BOLTON C, PAUL C. (1997). MK-801 limits neurovascular dysfunction during experiment allergic encephalomyelitis. J Pharmacol Exp Ther, 282: 397-402.
7. BOSCA I, BUENO A, GADEA M, CASANOVA B, CORET F. (2004). Donepezil and cognitive impairment in multiple sclerosis: a double-blind pilot study. Mult Scler, 10(Suppl. 2): S150.
8. BROCHET B, BONNET M, DELOIRE M, HAMEL D, SALORT-CAMPANA E. (2007). Les troubles cognitifs au cours de la sclérose en plaques. Rev Neurol (Paris), 163.
9. BRUNNER R, SCHAEFER D, HESS K, PARZER P, RESCH F, SCHWAB S. (2005). Effect of corticosteroids on short-term and long-term memory. Neurology, 64: 335-7.
10. CHIARAVALLOTI ND, DEMAREE H, GAUDINO EA, DELUCA J. (2003). Can the repetition effect maximize learning in multiple sclerosis? Clin Rehabil, 17: 58-68.
11. COHEN JA, CUTTER GR, FISHER JS et al. (2002). Benefit of interferon beta-1-a on MFSC progression in secondary progressive MS. Neurology, 59: 679-87.
12. DECCO D, ON BEHALF OF THE MS REHAB STUDY GROUP. (2004). Effects of donepezil in multiple sclerosis. Mult Scler, 10(Suppl. 2): S150
13. DIEPERINK E, WILLENBRING M, HO SB. (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon alpha : A review. Am J Psychiatry, 157: 867-76.
14. EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MS. (1998). Placebon-controlled multicenter randomised trial of interferon beta 1b in treatment of secondary progressive multiple sclerosis. Lancet, 352: 1491-7.
15. FISCHER JS, PRIORE RL, JACOBS LD et al. (2000). Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol, 48: 885-92.
16. GEISLER MW, SLIWINSKI M, COYLE PK, MASUR DM, DOSCHER C, KRUPP LB. (1996). The effects of amantadine and pemoline on cognitive functions in multiple sclerosis. Arch Neurol, 53: 185-8.
17. GEURTS JJ, WOLSWIJK G, BO L, VAN DER VALK P, POLMAN CH, TROOST D, ARONICA E. (2003). Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain, 126: 1755-66.
18. GOLDSTEIN G, BEERS SR, LONGMORE S, MCCUE M. (1996). Efficacity of memory training: a technological extension and replication. Clin Neuropsychol, 10: 66-72.
19. GREENE YM, TARIOT PN, WISHART H, COX C, HOLT CJ, SCHWID S, NOVIASKY J. (2000). A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol, 20: 350-6.
20. GROOM AJ, SMITH T, TURSKI L. (2003). Multiple sclerosis and glutamate. Ann N Y Acad Sci, 993: 229-75.
21. JONSSON A, KORFITZEN EM, HELTBERG A, RAVNBORG MH, BYSKOV-OTTOSEN E. (1993). Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand, 88: 394-400.
22. KRUPP LB, CHRISTODOULOU C, MELVILLE P, SCHERL WF, MAC ALLISTER WS, ELKINS LE. (2004). Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology, 63: 1579-85.
23. LEOCANI L, COMI E, ANNOVAZI P et al. (2007). Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality. Neurorehabil Neural Repair, (in press).
24. LINCOLN NB, DENT A, HARDING J, WEYMAN N, NICHOLL C, BLUMHARDT LD, PLAYFORD ED. (2002). Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry, 72: 93-8.
25. MACALLISTER WS, BELMAN AL, MILAZZO M et al. (2005). Cognitive functioning in children and adolescents with multiple sclerosis. Neurology, 64: 1422-5.
26. MAINERO C, CARAMIA F, POZZILLI C et al. (2004). fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. NeuroImage, 21: 858-67.
27. MONTALBAN X, RIO J. (2006). Interferons and cognition. J Neurol Sci, 245: 137-40.
28. MOOR AC, DE VRIES HE, DE BOER AG, BREIMER DD. (1994). The blood-brain barrier and multiple sclerosis. Biochem Pharmacol, 47: 1717-24.
29. MÜLLER UC, MONSCH AU, PLOHMAN AM et al. (2007). Cognitive rehabilitation of attentional functions in multiple sclerosis : a multi-center comparison of two training methods. Soumis.
30. OLIVERI RL, SIBILIA G, VALENTINO P, RUSSO C, ROMEO N, QUATTRONE A. (1998). Pulsed methylprodsolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand, 97: 366-9.
31. ORGOGOZO JM, RIGAUD AS, STOFFLER A, MOBIUS HJ, FORETTE F. (2002). Efficacity and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 33: 1834-9.
32. PARRY AM, SCOTT RB, PALACE J, SMITH S, MATTHEWS PM. (2003). Potentially adaptive functional changes in cognitive processing for patient with multiple sclerosis and their acute modulation by rivastigmine. Brain, 126: 2750-60
33. PATZOLD T, SCHWENGELBECK M, OSSEGE LM, MALIN JP, SINDERN E. (2002). Cnahges in the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand, 105: 164-8.
34. PAUL C, BOLTON C. (1995). Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-termtherapy with dexamethasone or cyclosporine A. Int J Immunopharmacol, 17: 497-503.
35. PAUL C, BOLTON C. (1998). Antagonism of N-methyl-D-aspartate (NMDA) receptor activity with memantine limits blood-brain barrier (BBB) dysfunction and disease developpement during experimental allergic encephalomyelitis - EAE). J Neuro immunol, 90: 24.
36. PAUL C, BOLTON C. (2002). Modulation of blod-brain-barrier dysfunction and neurological deficits during acute expérimental allergic encephalomyelitis by the N-methyl-d-aspartate receptor antagonist memantine. JPET, 302: 50-57.
37. PENNER IK, KAPPOS L, RAUSCH M, OPWIS K, RADU EW. (2006). Therapy-induced plasticity of cognitive functions in MS patients : Insights from fMRI. J Physiol, 99: 455-462.
38. PITT D, WERNER P, RAINE CS. (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nat Medicine, 6: 67-70.
39. PLISKIN NH, HAMER DP, GOLDSTEIN DS, TOWLE VL, REDER AT, NORONHA A, ARNASON BG. (1996). Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology, 47: 1463-8.
40. PLOHMANN AM, KAPPOS L, AMMANN W et al. (1998). Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 64(4): 455-62.
41. PORCEL J, MONTALBAN X. (2006). Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol Sci, 245: 177-181.
42. PRAKASH RS, SNOOK EM, ERICKSON KI, COLCOMBE SJ, VOSS MW, MOTL RW, KRAMER AF. (2007). Cardiorespiratory fitness: A predictor of cortical plasticity in multiple sclerosis. NeuroImage, 34: 1238-44.
43. RANJEVA JP, AUDOIN B, AU DUONG MV et al. (2006). Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J Neurol Sci, 245: 161-7.
44. RAO SM, LEO GJ, BERNARDIN L, UNVERZAGT F. (1991a). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41: 685-691.
45. RAO SM, LEO GJ, ELLINGTON L, NAUERTZ T, BERNARDIN L, UNVERZAGT F. (1991b). Cognitive dysfuntion in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 41: 692-6.
46. RAO SM. (1995). Neuropsychology of multiple sclerosis. Curr Opin Neurol, 8: 216-220.
47. REISBERG B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ, MEMANTINE STUDY GROUP. (2003). Memantine in moderate to severe Alzheimer's disease. N Engl J Med, 348: 1333-41.
48. ROSSINI PM, PASQUALETTI P, POZZILLI C et al. (2001). Fatigue in progressive multiple sclerosis: results of a randomized, doubleblind, placebo, crossover trial of oral 4-aminopyridine. Mult Scler, 7: 354-8.
49. SCHMITT FA, CRAGAR D, ASHFORD JW, REISBERG B, FERRIS S, MOBIUS HJ, STOFFLER A. (2002). Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm, 62 135-48.
50. SCHWID SR, GOODMAN AD, WEINSTEIN A, MCDERMOTT MP, JOHNSON KP, FOR THE COPAXONE STUDY GROUP. (2007). Cognitive function in relapsing multiple sclerosis : Minimal changes in a 10-year clinical trial. J Neurol Sci, 255: 57-63.
51. SELBY MJ, LING N, WILLIAMS JM, DAWSON A. (1998). Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Percept Mot Skills, 86(3 Pt1): 1099-106.
52. SMITH T, GROOM A, ZHU B, TURSKI L. (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Medicine, 6: 62-66.
53. SMITS RC, EMMEN HH, BERTESMANN FW, KULIG BM, VAN LOENEN AC, POLMAN CH. (1994). The effect of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology, 44: 1701-5.
54. SOLARI A, MOTTA A, MENDOZZI L, PUCCI E, FORNI M, MANCARDI G, POZZILLI C. (2004). Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-bind controlled trial. J Neurol Sc, 222: 99-104.
55. STAFFEN W, MAIR A, ZAUNER H et al. (2002). Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain, 125: 1275-82.
56. TAKAHASHI JL, GIULIANI F, POWER C, IMAI Y, YONG VW. (2003). Interleukin 1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol, 53: 588-595.
57. WEINSTEIN A, SCHWID SI, SCHIFFER RB, MCDERMOTT MP, GIANG DW, GOODMAN AD. (1999). Neuropsychological status in multiple sclerosis afetr treatement with glatiramer. Arch Neurol, 56: 319-324.
58. WERNER P, PITT D, RAINE CS. (2001). Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol, 50: 169-180.
59. WILCOCK G, MOBIUS HJ, STOFFLER A, MMM 500 GROUP. (2002). A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol, 17: 297-305.
60. ZEPHIR H, DE SEZE J, DUJARDIN K et al. (2005). One year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Mult Scler, 11: 360-363.